Tour the DUPIXENT virtual booth experience. Explore Today DUP.20.09.0243

Not an actual patient. Real patient treated with DUPIXENT.
Individual results may vary.

Sustained results

Lasting relief

Approved for patients
aged 6 years and older

In Uncontrolled Moderate-To-Severe Atopic Dermatitis
When topical Rx therapies are not enough, provide sustained results and lasting relief with a treatment that has clinical trial outcomes supported by real-world data in adults

Request a Field
Representative Visit

Connect with a DUPIXENT Field Representative to get answers to any product-related questions you might have.

The DUPIXENT 300 mg Pre-filled Pen is now available for appropriate patients aged 12+ years!1

Look Into Dosing Schedule and Weight-tiered Dosing

Consider DUPIXENT, dosed once every 4 weeks or every 2 weeks (depending on weight in pediatric patients), for your patients aged 6 years and older with moderate-to-severe atopic dermatitis who are uncontrolled on topical prescription therapies.

See Dosing and Administration

When Topical Rx Therapies Are Not Enough…

DUPIXENT Specifically Targets a Source of Systemic, Underlying Inflammation in Atopic Dermatitis1,2

Itch Relief and Skin Clearance1,3-6

Long-term Safety Profile1

Clinical Trial Outcomes
Supported by Real-world Data1,7,8

Trial Designs and Results

With DUPIXENT MyWay® Your Patients Will Have Access to the Following Resources:

  • Insightful tips and tools to help them along the way
  • Supplemental injection training
  • Help scheduling deliveries of their prescription
  • One-on-one nursing support for DUPIXENT
  • Helpful support resources for DUPIXENT

Enroll Today
To enroll in DUPIXENT MyWay, your patients can call 1‑844‑DUPIXEN(T) or you can use the following links to download the forms.
Explore Patient Support Resources
  1. DUPIXENT Prescribing Information.
  2. Eyerich K, Eyerich S. Immune response patterns in non communicable inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2018;32(5):629-703.
  3. Data on file, Regeneron Pharmaceuticals, Inc.
  4. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  5. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  6. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44-56.
  7. Guttman-Yassky E, Lio PA, Mallya UG, et al. Real-world effectiveness of dupilumab in atopic dermatitis: improvement in itch as assessed by the peak pruritus numerical rating scale (PNRS) in an electronic medical records dataset. Paper presented at: 24th World Congress of Dermatology (WCD); June 10-15, 2019; Milan, Italy.
  8. Eichenfield LF, Gadkari A, Armstrong AW, et al. Real-world effectiveness of dupilumab based on Investigator Global Assessment (IGA) scores and Peak Pruritus Numerical Rating Scale (PNRS) in an electronic medical records dataset. Poster presented at: 77th Annual Meeting of the Society for Investigative Dermatology (SID); May 8-11, 2019; Chicago, IL.

Important Safety Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.


Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.


  • Pregnancy: Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information


DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.